for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Sanofi SA

SASY.PA

Latest Trade

84.23EUR

Change

0.13(+0.15%)

Volume

120,671

Today's Range

83.73

 - 

84.39

52 Week Range

67.65

 - 

95.82

As of on the Euronext Paris ∙ Minimum 15 minute delay

Pricing

Previous Close
84.10
Open
84.00
Volume
120,671
3M AVG Volume
46.87
Today's High
84.39
Today's Low
83.73
52 Week High
95.82
52 Week Low
67.65
Shares Out (MIL)
1,253.60
Market Cap (MIL)
106,646.90
Forward P/E
14.66
Dividend (Yield %)
3.72

Next Event

Sanofi SA at Credit Suisse Virtual Bus Tour

Latest Developments

More

Kiadis Pharma and Sanofi Confirm Good Progress On Preparations For Offer

Sanofi: EC Approves MenQuadfi®, Latest Innovation In Meningococcal Vaccination For Individuals 12 Months Of Age And Older

Sanofi: European Commission Approves Supemtek®

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Sanofi SA

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company's pharmaceuticals operations. The Vaccines segment is dedicated to vaccines and includes the commercial operations of the Company's vaccines division Sanofi Pasteur and dedicated research and development, production and marketing activities for the Company's vaccines operations. Its Rare Diseases products include Cerezyme, Cerdelga, Myozyme and Lumizyme, Fabrazyme, and Aldurazyme. It partners with Alnylam Pharmaceuticals.

Industry

Biotechnology & Drugs

Contact Info

54 rue la Boetie

75008

France

+33.1.53774000

https://www.sanofi.com/

Executive Leadership

Serge Weinberg

Independent Chairman of the Board

Paul Hudson

Chief Executive Officer, Member of the Executive Committee, Director

Jean-Baptiste Chasseloup de Chatillon

Chief Financial Officer, Executive Vice President, Member of the Executive Committee

Karen Linehan

Executive Vice President - Legal Affairs and General Counsel, Member of the Executive Committee

Caroline Luscombe

Executive Vice President of Human Resources, Member of the Executive Committee

Key Stats

2.04 mean rating - 27 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2017

35.1K

2018

34.5K

2019

36.1K

2020(E)

36.8K
EPS (EUR)

2017

5.540

2018

5.470

2019

5.990

2020(E)

5.817
Price To Earnings (TTM)
9.50
Price To Sales (TTM)
2.83
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
8.43
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
--
Return on Equity (TTM)
--

Latest News

Latest News

Sanofi and Regeneron's Dupixent wins EU approval to treat children

Healthcare companies Sanofi and Regeneron said on Monday that their Dupixent product has won approval from the European Commission to treat children aged 6-11 suffering from severe atopic dermatitis, often known as eczema.

Healthcare group Sanofi invests 50 million euros in Jeito Capital

French healthcare giant Sanofi has invested 50 million euros ($59 million) into Jeito Capital, an investment firm dedicated to biotech and biopharma, in a deal which Sanofi said would support French and European healthcare innovation.

Sanofi believes Europe well prepared to address pandemics

Europe is better prepared than ever to ensure a COVID-19 vaccine reaches the population, Sanofi's <SASY.PA> chief executive said on Monday.

Sanofi continues to enroll patients for other diseases treatment: CEO

French drugmaker Sanofi <SASY.PA> continues to enroll patients for the treatment of diseases other than COVID-19 and maintains a 100% capacity to manufacture drugs, its chief executive said on Monday.

Sanofi continues to enroll patients for other diseases treatment - CEO

French drugmaker Sanofi continues to enroll patients for the treatment of diseases other than COVID-19 and maintains a 100% capacity to manufacture drugs, its chief executive said on Monday.

Sanofi has narrowed gap vs competitors in development of COVID-19 vaccine, CEO says

French drugmaker Sanofi has narrowed the gap against its rivals in the development of a COVID-19 vaccine, its Chief Executive said on Monday.

Sanofi has narrowed gap vs competitors in development of COVID-19 vaccine - CEO

French drugmaker Sanofi has narrowed the gap against its rivals in the development of a COVID-19 vaccine, its Chief Executive said on Monday.

Europe better prepared for ensuring COVID-19 vaccine reaches population- Sanofi CEO

Europe is much better prepared when it comes to ensuring a COVID-19 vaccine reaches the population, the head of drugmaker Sanofi said on Monday.

Healthcare group Sanofi offers to buy smaller peer Kiadis for 308 million euros

Sanofi <SASY.PA> is offering to buy Dutch biotechnology company Kiadis <KDS.AS> for 308 million euros ($358.4 million) to boost its range of immunotherapy products.

EU Commission says talking to four companies on COVID vaccine

The European Commission is in talks with four companies to secure a potential COVID-19 vaccine, President Ursula von der Leyen said on Thursday following an EU leaders' video conference.

Activists urge 'Big Pharma' to be transparent on COVID-19 vaccine costs

Activists called on pharmaceutical companies on Thursday to be transparent about the costs and terms of providing COVID-19 vaccines, saying they must be available and affordable for all.

Activists urge 'Big Pharma' to be transparent on COVID-19 vaccine costs

Activists called on pharmaceutical companies on Thursday to be transparent about the costs and terms of providing COVID-19 vaccines, saying they must be available and affordable for all.

Activists urge 'Big Pharma' to be transparent on COVID-19 vaccine costs

Activists called on pharmaceutical companies on Thursday to be transparent about the costs and terms of providing COVID-19 vaccines, saying they must be available and affordable for all.

Sanofi raises outlook as speciality care and vaccines lift sales

Sanofi <SASY.PA> raised its 2020 earnings guidance for the second time this year after posting slightly stronger-than-expected third-quarter results on Thursday, helped by growth at its speciality care and vaccines units.

Sanofi, GSK to supply vaccine doses to WHO-backed alliance

French drugmaker Sanofi <SASY.PA> and Britain's GlaxoSmithKline <GSK.L> will supply 200 million doses of their COVID-19 candidate vaccine to a global inoculation scheme backed by the World Health Organization.

BRIEF-Sanofi Says Co, GSK To Support COVAX With 200 Mln Doses Of COVID-19 Vaccine

* SANOFI SAYS CO AND GSK TO SUPPORT COVAX WITH 200 MILLION DOSES OF ADJUVANTED, RECOMBINANT PROTEIN-BASED COVID-19 VACCINE

GSK, Sanofi to make 200 mln doses available for COVID-19 vaccine alliance

French drugmaker Sanofi SA and Britain's GlaxoSmithKline plan to make 200 million doses of their COVID-19 vaccine candidate available to the vaccine allocation plan co-led by GAVI and the World Health Organization.

Sanofi reports positive animal test results for potential COVID-19 vaccine

Clinical trials of an experimental vaccine against COVID-19 which is being developed by France's Sanofi and U.S. biotech firm Translate Bio are on track to begin before the end of the year after positive results in tests on animals.

Novavax to explore combined influenza/COVID-19 vaccine for use post pandemic

Novavax Inc said on Tuesday it has set up a team of company veterans as it seeks U.S. regulatory approval for its seasonal influenza vaccine and to help develop a combined influenza/COVID-19 vaccine for use after the pandemic.

Exclusive: AstraZeneca gets partial immunity in low-cost EU vaccine deal

European governments will pay claims above an agreed limit against AstraZeneca over side-effects from its potential COVID-19 vaccine, under different terms to a deal struck with Sanofi, an EU official told Reuters.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up